Trial · NCT05071053
Results by group11
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 11 of 11
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part 1: Number of Participants With Study-Drug Related Dose Limiting Toxicities (DLTs) | Tusamitamab Ravtansine + Ramucirumab | 0 | Participants | ||
| Objective Response Rate (ORR) | Tusamitamab Ravtansine + Ramucirumab | 14.3 | 95% Confidence Interval 4.81 to 30.26 | percentage of participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) | Tusamitamab Ravtansine + Ramucirumab | Any TEAE | 35 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) | Tusamitamab Ravtansine + Ramucirumab | Any TESAE | 15 | Participants | |
| Duration of Response (DOR) | Tusamitamab Ravtansine + Ramucirumab | NA | 95% Confidence Interval 5.520 to NA | months | |
| Progression-free Survival (PFS) | Tusamitamab Ravtansine + Ramucirumab | 3.78 | 95% Confidence Interval 1.511 to 5.749 | months | |
| Disease Control Rate (DCR) | Tusamitamab Ravtansine + Ramucirumab | 62.9 | 95% Confidence Interval 44.92 to 78.53 | percentage of participants | |
| Individual Observed Predose Concentrations (Ctrough) of Tusamitamab Ravtansine | Tusamitamab Ravtansine + Ramucirumab | 14.7 | Standard Deviation 6.83 | microgram/milliliter (mcg/mL) | |
| Individual Observed Predose Concentrations (Ctrough) of Ramucirumab | Tusamitamab Ravtansine + Ramucirumab | 21.8 | Standard Deviation 10.48 | mcg/mL | |
| Number of Participants With Antitherapeutic Antibodies (ATAs) Against Tusamitamab Ravtansine | Tusamitamab Ravtansine + Ramucirumab | Treatment-induced ATA | 4 | Participants | |
| Number of Participants With Antitherapeutic Antibodies (ATAs) Against Tusamitamab Ravtansine | Tusamitamab Ravtansine + Ramucirumab | Treatment-boosted ATA | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05071053/results